CoChat

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

Turner, Nicholas C, Neven, Patrick, Loibl, Sibylle, Andre, Fabrice · 2017 · The Lancet

Abstract

Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival. A new wave of targeted therapies is being developed, including inhibitors of PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders. Considerable challenges remain in patient selection, deciding on the most appropriate order in which to administer therapies, and establishing whether cross-resistance occurs between therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)32419-9

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 106 references

Cited by

See all 230

Metadata

Authors
Turner, N. C., Neven, P., Loibl, S., & Andre, F.
Affiliations
  • Institute of Cancer Research (GB)
  • Universitair Ziekenhuis Leuven (BE)
  • German Breast Group (DE)
Corresponding author
Loibl, Sibylle
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-06
Volume
389
Issue
10087
Pages
2403-2414
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2560409587
Cited by
205
References
106
Citations by year
2026: 14 · 2025: 10 · 2024: 18 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 31 · 2019: 21 · 2018: 29 · 2017: 10
FWCI
3.46
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
estrogen receptor-positive breast cancer, advanced breast cancer, endocrine therapy, endocrine therapy resistance, mTOR inhibitors, CDK4/6 inhibitors, PI3K/AKT inhibitors, HER2 inhibitors, targeted therapy, progression-free survival, cross-resistance, patient selection
MeSH terms
Antineoplastic Agents, Breast Neoplasms, Female, Humans, Nuclear Proteins, Piperazines, Pyridines, Receptors, Estrogen, Transcription Factors, Aromatase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. https://app.cochat.ai/papers/10.1016/s0140-6736(16)32419-9
The paper
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017). Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. The Lancet. https://doi.org/10.1016/s0140-6736(16)32419-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.